Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/8/2025 | Outperform | William Blair | |
| 3/18/2025 | $17.00 | Outperform | RBC Capital Mkts |
| 3/11/2025 | $15.00 | Buy | Needham |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 6/20/2024 | $7.00 → $11.00 | Hold → Buy | TD Cowen |
| 5/31/2024 | $15.00 | Overweight | Piper Sandler |
| 2/9/2024 | $15.00 | Buy | BofA Securities |
| 4/21/2023 | $18.00 | Outperform | Robert W. Baird |
William Blair initiated coverage of Ocular Therapeutix with a rating of Outperform
RBC Capital Mkts initiated coverage of Ocular Therapeutix with a rating of Outperform and set a new price target of $17.00
Needham initiated coverage of Ocular Therapeutix with a rating of Buy and set a new price target of $15.00
BEDFORD, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, announced the launch of its new corporate branding and website today, marking the next milestone of the Company's transformation to a retina-focused company. Ocular Therapeutix Logo Designed with visual accessibility at its core, the logo is science-based, transformative, and joyful. The circular "O" represents the eye and the retina, while the full-spectrum color palette captures the vibrancy of human vision and the richness of life it enables. The treatment of the "X" represents the intersection of where the c
BEDFORD, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2025, taking place on June 21, 2025, in Las Vegas, NV. Clinical Trials at the Summit (CTS) 2025 Presentation Details: Company Presentation: Ocular TherapeutixSession: Diamond Sponsor TalksPresentation Date/Time: Friday, June 20, 2025, 7:55 – 8:05 PM PTPresenter: Sanjay Nayak, MBBS, PhD, Chief Strategy Officer Presentation Title: Sustained-Release Axitinib Hydrogel (OTX-TKI) for Wet AMD: US Phase 1 Study ResultsSession: Tyrosine Kinase
Enrollment for SOL-R, the largest retinal TKI trial to date, supports randomization of at least 555 subjects SOL-1, Ocular's first registrational trial in wet AMD, completed randomization in December 2024 and retention remains exceptional as the trial continues on track for top-line readout in 1Q 2026 These two complementary trials are intended to form the basis of an NDA submission of AXPAXLI in wet AMD BEDFORD, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced that enrollment in the SOL-R registrational trial of its product candidate AXPA